Technology company providing genetic testing services primarily for inherited conditions and cancers.
Fulgent Genetics, Inc., along with its subsidiaries, specializes in providing a wide array of molecular diagnostic and genetic testing services across the United States and globally. The company is renowned for its comprehensive offerings, including COVID-19 testing, genetic tests like oncology panels such as Focus and Comprehensive, carrier screening panels like Beacon, and solid tumor molecular profiling for somatic cancer testing.
The company also excels in rapid whole genome testing for children in NICU and PICU settings, newborn genetic analysis panels, and single front-line tests designed to detect ataxia-related variants and repeat expansions through sequencing. Fulgent Genetics further extends its capabilities with patient-initiated genetic testing through Picture Genetics, whole exome and clinical exome panel tests, as well as whole genome, mutation, and repeat expansion testing services, catering to both clinical and research needs.
In addition to genetic testing, Fulgent Genetics offers a range of advanced diagnostic services, including next-generation sequencing, reverse transcription polymerase chain reaction-based tests, and antigen-based diagnostic tests specifically designed for the detection of SARS-CoV-2. The company's diagnostic portfolio also includes flow cytometry for cell analysis, fluorescence in-situ hybridization for DNA sequence detection, immunohistochemistry for antigen visualization in cells, and cytogenetics for chromosome set analysis to identify numerical and structural abnormalities.
Fulgent Genetics serves a diverse client base that includes insurance companies, hospitals, medical institutions, laboratories, governmental bodies, payors, municipalities, large corporations, and individual patients. The company has strengthened its market position through strategic partnerships, notably including a collaboration with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, Fulgent Genetics, Inc. continues to lead in genetic and molecular diagnostic innovation.